| Drug ID: | Drug58 |
|---|---|
| Drug Name: | Atorvastatin |
| CID: | 60823 |
| DrugBank ID: | DB01076 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05561062, , NCT05567068 |
| Molecular Formula: | C33H35FN2O5 |
| Molecular Weight: | 558.6 g/mol |
| Isomeric SMILES: | CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4 |
| Synonyms: | atorvastatin; 134523-00-5; Tozalip; Xavator; atorvastatina; atorvastatine; Atofast; Atorcor; Atorlip; Lipilou |
| Phase 0: | 14 |
| Phase 1: | 167 |
| Phase 2: | 225 |
| Phase 3: | 293 |
| Phase 4: | 336 |
| Description: | Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt530 | 60823 | Atorvastatin | 3156 | HMGCR | Homo sapiens (human) | 24194513 | Inhibitor, prodrug |
| dt531 | 60823 | Atorvastatin | 1027 | CDKN1B | Homo sapiens (human) | 18172863 | [atorvastatin co-treated with celecoxib] results in increased expression of CDKN1B protein |
| dt532 | 60823 | Atorvastatin | 19 | ABCA1 | Homo sapiens (human) | 16386711 | Atorvastatin results in decreased expression of ABCA1 protein|atorvastatin results in decreased expression of ABCA1 mRNA |
| dt533 | 60823 | Atorvastatin | 19 | ABCA1 | Homo sapiens (human) | 15183127 | [rosiglitazone co-treated with atorvastatin] results in increased expression of ABCA1 protein |
| dt534 | 60823 | Atorvastatin | 19 | ABCA1 | Mus musculus (house mouse) | 25278499 | Atorvastatin results in increased expression of ABCA1 mRNA |
| dt535 | 60823 | Atorvastatin | 5243 | ABCB1 | Homo sapiens (human) | 19802823 | ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to atorvastatin]|abcb1 results in increased transport of atorvastatin |
| dt536 | 60823 | Atorvastatin | 5243 | ABCB1 | Homo sapiens (human) | ABCB1 protein results in increased transport of atorvastatin | |
| dt537 | 60823 | Atorvastatin | 5243 | ABCB1 | Homo sapiens (human) | 15616150 | ABCB1 protein results in increased transport of atorvastatin analog|atorvastatin analog results in decreased activity of ABCB1 protein|atorvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] |
| dt538 | 60823 | Atorvastatin | 8647 | ABCB11 | Homo sapiens (human) | 15901796 | Atorvastatin inhibits the reaction [ABCB11 protein affects the import of taurocholic acid] |
| dt539 | 60823 | Atorvastatin | 8647 | ABCB11 | Homo sapiens (human) | 24014644 | Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of taurocholic acid] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT04767984 | Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis | PHASE2 | RECRUITING | Northwestern University | Colorectal Carcinoma|Ulcerative Colitis | DRUG: Atorvastatin Calcium|PROCEDURE: Biopsy of C… | Details |
| NCT05567068 | Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis | PHASE2 | RECRUITING | Tanta University | Inflammatory Bowel Diseases | DRUG: Atorvastatin 80mg|DRUG: Mesalamine | Details |
| EUCTR2005-000496-17-SE | Atorvastatin in moderat active Crohns disease | Not Available | Not Recruiting | Region Skåne | Crohn's disease is an idiopathic chronic inflamma… | Product Name: atorvastatin Pharmaceutical Form: T… | Details |
| NCT05561062 | Atorvastatin in Patients With Ulcerative Colitis | PHASE2 | RECRUITING | Tanta University | Inflammatory Bowel Diseases | DRUG: Atorvastatin 80mg | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Repurposing Atorvastatin, HMGCO-A Reductase Inhibitor, in Patients with Ulcerat…
PMID: 40364108
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Background/Objective: Among the inflammatory bowel illnesses, ulcerative colitis (UC) affects 5 million people worldwide. UC manifests as weight loss…
Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflamma…
PMID: 35585214
Year: 2022
Relationship Type:
Pharmacology
Score: 6.5
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are common disorders that can change the body's physiology and drugs pharmacokine…
Computational drug repositioning of atorvastatin for ulcerative colitis
PMID: 34529084
Year: 2021
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: Ulcerative colitis (UC) is a chronic inflammatory disorder with limited effective therapeutic options for long-term treatment and disease …
Targeting IL-10, ZO-1 gene expression and IL-6/STAT-3 trans-signaling by a comb…
PMID: 32383169
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis (UC) is a chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa. The pathogenesis of …
Atorvastatin promotes the expansion of myeloid-derived suppressor cells and att…
PMID: 27548304
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Statins, widely prescribed as cholesterol-lowering drugs, have recently been extensively studied for their pleiotropic effects on immune systems, esp…
The effect of atorvastatin and its role on systemic cytokine network in treatme…
PMID: 21428710
Year: 2011
Relationship Type:
Treatment
Score: 6.1
Inflammatory bowel diseases are characterized by disabilities in gastrointestinal system and defects in mucosal immune system. Statins are 3-hydroxy-…